Gilead Sciences

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About GILD

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. 

CEO
Daniel P. O'Day
CEODaniel P. O'Day
Employees
17,000
Employees17,000
Headquarters
Foster City, California
HeadquartersFoster City, California
Founded
1987
Founded1987
Employees
17,000
Employees17,000

GILD Key Statistics

Market cap
162.40B
Market cap162.40B
Price-Earnings ratio
19.00
Price-Earnings ratio19.00
Dividend yield
2.48%
Dividend yield2.48%
Average volume
5.96M
Average volume5.96M
High today
$132.21
High today$132.21
Low today
$127.96
Low today$127.96
Open price
$127.96
Open price$127.96
Volume
6.49M
Volume6.49M
52 Week high
$157.29
52 Week high$157.29
52 Week low
$95.30
52 Week low$95.30

Stock Snapshot

As of today, Gilead Sciences(GILD) shares are valued at $131.65. The company's market cap stands at 162.4B, with a P/E ratio of 19.00 and a dividend yield of 2.5%.

As of 2026-05-01, Gilead Sciences(GILD) stock has fluctuated between $127.96 and $132.21. The current price stands at $131.65, placing the stock +2.9% above today's low and -0.4% off the high.

Gilead Sciences(GILD) shares are trading with a volume of 6.49M, against a daily average of 5.96M.

During the past year, Gilead Sciences(GILD) stock moved between $95.30 at its lowest and $157.29 at its peak.

During the past year, Gilead Sciences(GILD) stock moved between $95.30 at its lowest and $157.29 at its peak.

GILD News

Simply Wall St 1h
Gilead Advances HIV And Oncology Pipeline As Shares Trade Below Targets

Gilead Sciences (NasdaqGS:GILD) received FDA acceptance and priority review for its New Drug Application for a once daily HIV regimen. The company also complet...

Gilead Advances HIV And Oncology Pipeline As Shares Trade Below Targets
Simply Wall St 1d
Assessing Whether Gilead Sciences Looks Undervalued After Recent Share Price Performance

With no single headline event driving Gilead Sciences (GILD) today, the focus shifts to how the stock’s recent performance, business mix and valuation metrics m...

Assessing Whether Gilead Sciences Looks Undervalued After Recent Share Price Performance
TipRanks 2d
Gilead announces U.S. FDA accepted NDA submission for bictegravir, lenacapavir

Gilead (GILD) Sciences announced the U.S. Food and Drug Administration, FDA, accepted its New Drug Application, NDA, submission for bictegravir 75 mg/lenacapavi...

Analyst ratings

75%

of 32 ratings
Buy
75%
Hold
21.9%
Sell
3.1%

More GILD News

Barron's 3d
Gilead Sciences Crosses Critical Breakout Level. The Stock Can Gain 35% From Here.

Technical Analysis Gilead Sciences Crosses Critical Breakout Level. The Stock Can Gain 35% From Here. In this article GILD XBI IBB Gilead headquarters in Foster...

Gilead Sciences Crosses Critical Breakout Level. The Stock Can Gain 35% From Here.
TipRanks 3d
Gilead Sciences Completes Acquisition of Arcellx and Anito-cel

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

TipRanks 3d
Gilead completes acquisition of Arcellx for $115 per share in cash

Gilead Sciences (GILD) announced the completion of its previously announced acquisition of Arcellx (ACLX). Under the terms of the transaction, Gilead acquired A...

People also own

Based on the portfolios of people who own GILD. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.